Carlos Martinez, MD
Ophthalmology · Long Beach, CANPI 1710093083
Payments from drug & device makers
Across 537 payments — averaging $315.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$108K
- AbbVie$26K
- Alcon$12K
- Bausch & Lomb Americas Inc.$9K
- Alcon Research LLC$7K
- Samsara Vision$1K
- plus $5K from 26 others
Across 1 payment — averaging $183.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$184
What the payments were for
- Consulting fees$22,52535%
- Speaking & faculty fees$15,40024%
- Travel & lodging$8,47513%
- Food & beverage$18,24128%
- Education$1240%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 90 | $108,166 |
| AbbVie(2 entities) | 98 | $26,091 |
| Alcon | 155 | $12,273 |
| Bausch & Lomb Americas Inc. | 29 | $9,166 |
| Alcon Research LLC | 5 | $7,059 |
| Samsara Vision | 13 | $1,245 |
| Aerie Pharmaceuticals, Inc. | 10 | $802 |
| Sight Sciences, Inc. | 19 | $757 |
| Carl Zeiss Meditec USA, Inc. | 9 | $604 |
| Sun Pharmaceutical Industries Inc. | 11 | $363 |
| Amgen(2 entities) | 17 | $340 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $262 |
| Rxsight Inc | 6 | $232 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $217 |
| Ivantis, Inc | 2 | $199 |
| Oyster Point Pharma, Inc. | 9 | $197 |
| NEW World Medical,inc. | 4 | $179 |
| Novartis | 16 | $178 |
| Carl Zeiss Meditec, Inc. | 2 | $134 |
| Eyevance Pharmaceuticals LLC | 2 | $126 |
| Dompe US, Inc. | 5 | $111 |
| Tarsus Pharmaceuticals, Inc. | 4 | $87 |
| Ocular Therapeutix, Inc. | 4 | $86 |
| Harrow Eye, LLC | 3 | $67 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| Optos, Inc. | 1 | $45 |
| Biotissue Holdings Inc. | 2 | $34 |
| Johnson & Johnson Vision Care, Inc. | 1 | $33 |
| Nova Eye, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Thea Pharma Inc. | 1 | $18 |
| LKC Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN$16,170
- iStent inject Trabecular Micro-Bypass Stent System$3,471
- DURYSTA$2,875
- AcrySof IQ PanOptix$2,517
- LenSx$2,110
- PanOptix$1,162
- AcrySof$1,050
- AcrySof IQ VIVITY IOL$999
- Implantable Miniature Telescope$969
- Rocklatan$710
- ReSTOR$488
- Clareon$342
- Hydrus Microstent$292
- QUATERA 700$153
- IOLMaster 700$153
- TearCare SmartLid$150
- TEARCARE(TM) (2.2) SYSTEM KIT$150
- TEARCARE SYSTEM$148
- VisuMax$145
- MIEBO$143
How this compares
$169,174 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 161 | $177,441 |
| XiidraLifitegrast | 70 | $100,648 |
| Cyclosporine | 111 | $77,314 |
| LumiganBimatoprost | 138 | $62,369 |
| RhopressaNetarsudil Mesylate | 120 | $59,352 |
| RocklatanNetarsudil Mesylat/Latanoprost | 91 | $49,107 |
| Restasis MultidoseCyclosporine | 21 | $23,573 |
| Alphagan PBrimonidine Tartrate | 56 | $22,492 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 95 | $22,338 |
| Latanoprost | 1,455 | $18,953 |
| Prednisolone Acetate | 469 | $18,318 |
| VyzultaLatanoprostene Bunod | 29 | $14,896 |
| Travoprost | 62 | $14,492 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $14,267 |
| Brinzolamide | 60 | $11,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Alphagan P, Combigan | $26,091 | $300,143409 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $9,166 | $125,271112 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $802 | $108,459211 claims |
| AlconSimbrinza, Azopt | $12,273 | $28,073110 claims |
| NovartisTravatan Z | $178 | $10,09121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Long Beach
- Julie GasperiniLong Beach$814K
- Carl HartmanLong Beach$716K
- Dan TranLong Beach$649K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.